The U.S. is seeing a substantial rise in subcutaneous implantable cardioverter defibrillator (ICD) use, a national registry suggests. Compared with those receiving single- and dual-chamber devices, patients receiving the subcutaneous alternative were more likely to be younger, female, black, undergoing dialysis, and have a history of cardiac arrest.